Five-year analysis of neoadjuvant dabrafenib and trametinib for stage III melanoma.
Menzies AM, Lo SN, Saw RPM, Gonzalez M, Ch'ng S, Nieweg OE, Shannon KF, Ferguson PM, Lee J, Emmett L, Kapoor R, Rawson RV, Stretch JR, Thompson JF, Spillane AJ, Rizos H, Scolyer RA, Long GV.
Menzies AM, et al. Among authors: lo sn.
Ann Oncol. 2024 May 14:S0923-7534(24)00141-8. doi: 10.1016/j.annonc.2024.05.002. Online ahead of print.
Ann Oncol. 2024.
PMID: 38754780